Royalty Pharma RPRX Institutional Ownership

Updated Oct 11, 2026

Royalty Pharma plc (NASDAQ:RPRX) was held by 641 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Collectively, these holders controlled 82.31% of Royalty Pharma's outstanding shares in Q2 2026, up from 80.46% in Q1 2026.
• Total holdings of RPRX shares rose 2.67% from Q1 2026, and the holder count rose 42.13% from Q2 2025.
• Of these 641 holders, 394 added to their positions, 178 reduced their stakes and 69 left their positions unchanged.
• The aggregate institutional position in Royalty Pharma was 366.5Mn shares at the end of Q2 2026, up 9.55Mn from the prior quarter and up 71.05Mn from a year earlier.
• As of June 30, 2026, Morgan Stanley held the largest stake in Royalty Pharma with 42.93Mn shares, or 9.64% of shares outstanding.
• Among existing holders, the largest additions to Royalty Pharma in Q2 2026 came from T. Rowe Price Associates Inc (+9.26Mn shares), BlackRock, Inc. (+1.93Mn shares), Nordea Investment Management AB (+1.79Mn shares), Capital World Investors (+1.48Mn shares) and State Street Corp (+1.35Mn shares).
• Among holders that kept a stake in Royalty Pharma, the biggest sellers in Q2 2026 were Baillie Gifford & Co (-6.14Mn shares), Adage Capital Partners GP, L.L.C. (-4.98Mn shares), UBS Asset Management Americas (-3.09Mn shares), Jane Street Group, LLC (-2.35Mn shares) and Caledonia (Private) Investments Pty Ltd (-1.39Mn shares).
• Royalty Pharma's 10 largest institutional shareholders as of Q2 2026 were Morgan Stanley (42.93Mn shares), Capital International Investors (35.27Mn shares), BlackRock, Inc. (27.83Mn shares), FMR LLC (24.51Mn shares), State Street Corp (12.34Mn shares), T. Rowe Price Associates Inc (11.19Mn shares), Swedbank AB (10.73Mn shares), Baillie Gifford & Co (10.02Mn shares), Capital World Investors (9.52Mn shares) and Geode Capital Management, LLC (8.06Mn shares), per Business Quant data.